Nova Biomedical Adds Productivity Assays to Cell Platforms
New integration provides earlier access to clone performance data during cell line development in Waltham.
Updated on Oct. 22, 2026 in Biotech
Live Poll
Does integrating automated data tools into research workflows improve scientific decision-making in your area?
Nova Biomedical has integrated PAIA Titer assay technology into its VIPS PRO and Cell Metric X platforms. This integration allows scientists to collect productivity and product quality data concurrently with clonality evidence during cell line development.
Why it matters
By providing early visibility into clone productivity, this workflow integration helps researchers avoid wasting time and resources on expanding cell lines that fail to meet performance requirements.
The integration combines PAIA Titer assay technology with existing clonality metrics from the VIPS PRO and Cell Metric X platforms. These systems provide high-resolution, multi-plane whole-well imaging and nanodroplet single-cell seeding, now paired with real-time productivity data.
The players
Nova Biomedical
A manufacturer of analytical instrumentation that specializes in cell culture monitoring and cell line development platforms.
The details
The VIPS PRO platform utilizes nanodroplets—minute volumes of liquid containing individual cells—for single-cell seeding and AI-assisted detection. It pairs this with double-lock clonality assurance, a process that verifies a single cell using both droplet and whole-well imaging. The Cell Metric X system adds high-resolution, multi-plane whole-well imaging that can operate within fully integrated robotic environments to monitor cell growth and viability.
Timeline
Day 0: VIPS PRO platform generates initial image-based clonality evidence.
The Tech Race
This development follows an industry trend of consolidating analytical steps within automated cell line development workflows. It marks a shift from standalone imaging solutions toward multi-modal platforms that synthesize phenotypic and performance data early in the process.
Bioprocess scientists can now prioritize promising clones as early as Day 0, reducing the need for downstream screening of low-performing candidates. The integration is immediately available for users of existing VIPS PRO and Cell Metric X hardware environments.
The takeaway
The addition of productivity assays into existing imaging hardware signals a transition toward more efficient, data-dense early-stage cell selection. Researchers should monitor whether this integration reduces the typical cycle time for clone selection in their upcoming development campaigns.
Further reading
Explore more developments in Biotech to see how automated workflows are reshaping cell line development.
Source note: This article includes information reported by Selectscience.
Live Poll
Does integrating automated data tools into research workflows improve scientific decision-making in your area?
